AGM
NYMX

Alpine Global Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Alpine Global Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-17,196
Closed -$38K – 481
2019
Q4 		$38K Buy
+17,196
New +$33.9K 0.01% 400

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Alpine Global Management's NYMX Position: Q1 2020 in Review

Alpine Global Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2020, closing a stake of 17,196 shares — an estimated $38K sold.

Alpine Global Management first reported a position in NYMX in Q4 2019 and held it in 1 quarter. The position peaked at $38K in Q4 2019. 47 funds tracked by Wall St. Rank hold NYMX as of Q1 2020.

  • Alpine Global Management reported no remaining Nymox Pharmaceutical Corp position as of Q1 2020 after selling out during the quarter.
  • Alpine Global Management sold 17,196 Nymox Pharmaceutical Corp shares in Q1 2020, an estimated $38K.
  • Alpine Global Management first reported a position in Nymox Pharmaceutical Corp in Q4 2019 and held it in 1 quarter.
  • Alpine Global Management's Nymox Pharmaceutical Corp position peaked at $38K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.